Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL25434708 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL13293175 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL1782809 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL13263378 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL7067155 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL12193300 | 0.88 | CHRM2 (0.37) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL8354068 | 0.88 | MAPK1 (0.38) | CHRM2CHRM1CHRM3NR1H2KDM4E | |
| SCHEMBL1785924 | 0.88 | MAPK1 (0.38) | CHRM2CHRM1CHRM3NR1H2KDM4E | |
| SCHEMBL12295967 | 0.88 | CHRM2 (0.37) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL2605610 | 0.85 | PTPN1 (0.37) | CHRM2CHRM1CHRM3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1314041-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | Annovis, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | ANNOVIS, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002018941-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | ANNOVIS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0809624-B1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | BEARSDEN BIO INC (US) | 2001-08-29 | — | — | EP | disclosed |
| US-5731348-A | NERVOUS SYSTEM DISORDERS | BEARSDEN BIO, INC. (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0809624-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | Bearsden Bio, Inc. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025387-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | SYMPHONY PHARMACEUTICALS, INC. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | SLC18A2, SLC1A2, SLC1A1 | CHRM2 449/4885CHRM1 389/4885CHRM3 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.